Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) EBT: 2011-2025

Historic EBT for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$20.4 million.

  • Abeona Therapeutics' EBT rose 32.74% to -$20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.9 million, marking a year-over-year increase of 21.65%. This contributed to the annual value of -$68.4 million for FY2024, which is 43.88% down from last year.
  • Latest data reveals that Abeona Therapeutics reported EBT of -$20.4 million as of Q3 2025, which was down 69.24% from -$12.0 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year EBT high stood at -$8.2 million for Q2 2022, and its period low was -$46.7 million during Q4 2021.
  • Its 3-year average for EBT is -$17.8 million, with a median of -$15.3 million in 2024.
  • Per our database at Business Quant, Abeona Therapeutics' EBT spiked by 71.90% in 2022 and then crashed by 196.31% in 2024.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' EBT stood at -$46.7 million in 2021, then soared by 71.90% to -$13.1 million in 2022, then declined by 1.56% to -$13.3 million in 2023, then crashed by 33.31% to -$17.8 million in 2024, then spiked by 32.74% to -$20.4 million in 2025.
  • Its EBT stands at -$20.4 million for Q3 2025, versus -$12.0 million for Q2 2025 and -$20.7 million for Q1 2025.